Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to $365,000.

  • Gyre Therapeutics' Cash from Financing Activities rose 12.65% to $365,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 52.79%. This contributed to the annual value of $2.1 million for FY2024, which is 15.92% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Cash from Financing Activities is $365,000, which was down 98.37% from $22.4 million recorded in Q2 2025.
  • Gyre Therapeutics' Cash from Financing Activities' 5-year high stood at $49.5 million during Q1 2021, with a 5-year trough of -$45.0 million in Q3 2022.
  • Over the past 3 years, Gyre Therapeutics' median Cash from Financing Activities value was $365,000 (recorded in 2025), while the average stood at $2.6 million.
  • In the last 5 years, Gyre Therapeutics' Cash from Financing Activities tumbled by 48,612.50% in 2023 and then skyrocketed by 14,227.56% in 2025.
  • Over the past 5 years, Gyre Therapeutics' Cash from Financing Activities (Quarterly) stood at $98,000 in 2021, then tumbled by 46,045.92% to -$45.0 million in 2022, then spiked by 96.72% to $15.2 million in 2023, then slumped by 93.67% to $964,000 in 2024, then grew by 12.65% to $365,000 in 2025.
  • Its Cash from Financing Activities stands at $365,000 for Q3 2025, versus $22.4 million for Q2 2025 and $1.3 million for Q1 2025.